Firm News
Wiggin and Dana advises BioArctic AB in global license agreement with Bristol Myers Squibb
Wiggin and Dana recently represented BioArctic AB (publ) (Nasdaq Stockholm: BIOA) in connection with its global license agreement with Bristol Myers Squibb (NYSE: BMY) for BioArctic’s PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program, including BAN1503 and BAN2803, the latter of which includes BioArctic’s BrainTransporter™ technology. Under the agreement, BioArctic will receive a $100 million up-front payment, up to $1.25 billion in milestone payments, and tiered low double-digit royalties on global product sales, with BioArctic retaining an option to co-commercialize the products in the Nordic region.
The Wiggin deal team consisted of Toby Bannon, Patti Melick, and Kelsey Loomis.
To learn more and read the official press release, please click here.